Importantly, deletion of HRI in other cell types, glioblastoma, 293T, pancreatic carcinoma and melanoma, resulted in increased toxicity of IXZ (Fig. S5), suggesting that a potential HRI inhibitor can be used in combination with PIs for additional tumors. Here, EIF2AK1 is linked to exocrine pancreatic carcinoma.